| General Information | |
|---|---|
| ZINC ID | ZINC000072119838 |
| Molecular Weight (Da) | 342 |
| SMILES | CCCCCn1cc(C(=O)c2cccc3ccccc23)c2cnccc21 |
| Molecular Formula | C23N2O1 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 103.265 |
| HBA | 2 |
| HBD | 0 |
| Rotatable Bonds | 6 |
| Heavy Atoms | 26 |
| LogP | 5.049 |
| Activity (Ki) in nM | 50.119 |
| Polar Surface Area (PSA) | 34.89 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | + |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.07 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 19 |
| Fraction csp3 | 0.22 |
| Ilogp | 3.56 |
| Xlogp3 | 5.25 |
| Wlogp | 5.61 |
| Mlogp | 3.1 |
| Silicos-it log p | 5.42 |
| Consensus log p | 4.59 |
| Esol log s | -5.42 |
| Esol solubility (mg/ml) | 0.00132 |
| Esol solubility (mol/l) | 0.00000384 |
| Esol class | Moderately |
| Ali log s | -5.73 |
| Ali solubility (mg/ml) | 0.000635 |
| Ali solubility (mol/l) | 0.00000185 |
| Ali class | Moderately |
| Silicos-it logsw | -8.2 |
| Silicos-it solubility (mg/ml) | 0.00000217 |
| Silicos-it solubility (mol/l) | 6.34E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.66 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 2.55 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.048 |
| Logd | 4.409 |
| Logp | 5.473 |
| F (20%) | 0.592 |
| F (30%) | 0.448 |
| Mdck | 1.38E-05 |
| Ppb | 0.9754 |
| Vdss | 3.553 |
| Fu | 0.0093 |
| Cyp1a2-inh | 0.956 |
| Cyp1a2-sub | 0.255 |
| Cyp2c19-inh | 0.909 |
| Cyp2c19-sub | 0.067 |
| Cl | 5.97 |
| T12 | 0.037 |
| H-ht | 0.144 |
| Dili | 0.965 |
| Roa | 0.151 |
| Fdamdd | 0.468 |
| Skinsen | 0.219 |
| Ec | 0.003 |
| Ei | 0.798 |
| Respiratory | 0.605 |
| Bcf | 1.975 |
| Igc50 | 5.173 |
| Lc50 | 6.355 |
| Lc50dm | 6.471 |
| Nr-ar | 0.035 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.903 |
| Nr-aromatase | 0.974 |
| Nr-er | 0.544 |
| Nr-er-lbd | 0.617 |
| Nr-ppar-gamma | 0.011 |
| Sr-are | 0.892 |
| Sr-atad5 | 0.73 |
| Sr-hse | 0.827 |
| Sr-mmp | 0.805 |
| Sr-p53 | 0.507 |
| Vol | 376.557 |
| Dense | 0.909 |
| Flex | 0.273 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 4 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 2 |
| Qed | 0.337 |
| Synth | 2.175 |
| Fsp3 | 0.217 |
| Mce-18 | 20 |
| Natural product-likeness | -0.999 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Accepted |